CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials

Rhea-AI Filing Summary

On August 11, 2025, Cadrenal Therapeutics, Inc. filed a Form 8-K reporting that it issued a press release containing financial information for the fiscal quarter ended June 30, 2025, furnished as Exhibit 99.1 to the report. The filing identifies the company as an emerging growth company and shows its common stock is listed on the Nasdaq Capital Market under the symbol CVKD. The filing also furnishes the cover page interactive XBRL as Exhibit 104 and was signed by Quang X. Pham, Chairman and Chief Executive Officer.

The company states the press release and Item 2.02 disclosure are furnished, not "filed" for purposes of Section 18, and will not be incorporated by reference into other SEC filings.

Positive

• Furnished a press release with financial information for the fiscal quarter ended June 30, 2025, attached as Exhibit 99.1.
• Disclosed Nasdaq listing and ticker: common stock listed on the Nasdaq Capital Market under CVKD.
• Provided XBRL cover page as Exhibit 104, supporting interactive data tagging for the filing cover page.

Negative

• The 8-K text does not include the actual financial figures; readers must consult Exhibit 99.1 for results and metrics.
• The company states the press release is furnished, not "filed" and not incorporated by reference, limiting reliance under Section 18 and incorporation protections.

Insights

Financial Analyst

TL;DR: Cadrenal furnished Q2 2025 financial results via a press release, but this 8-K text contains no underlying financial figures; see Exhibit 99.1.

The filing confirms the company issued a press release with financial information for the quarter ended June 30, 2025, which is material in timing and subject matter for investors. However, the 8-K here does not reproduce any revenue, earnings, cash flow, or guidance figures, so analysts must review the attached Exhibit 99.1 to evaluate actual performance. The presence of an XBRL cover page (Exhibit 104) indicates standardized tagging of cover page data but not that financial statements are included in this filing.

Corporate Governance Expert

TL;DR: Routine Form 8-K furnishing; the company expressly disclaims Section 18 liability and incorporation by reference for the press release.

This Form 8-K follows a common disclosure pattern: it furnishes a press release as Exhibit 99.1 and clarifies that the furnished materials are not "filed" for Section 18 purposes and will not be incorporated into other SEC filings. That disclaimer is standard but important for legal exposure and investor reliance. The filing is signed by the CEO, indicating appropriate executive attestation of the submission.

false 0001937993 0001937993 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2025

Cadrenal Therapeutics, Inc.

(Exact name of registrant as specified in charter)

Delaware		001-41596		88-0860746
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer  Identification No.)

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(Address of principal executive offices and zip code)

(904) 300-0701

(Registrant’s telephone number including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CVKD		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit Number		Exhibit Description
99.1		Press Release, issued by Cadrenal Therapeutics, Inc. on August 11, 2025
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 11, 2025	CADRENAL THERAPEUTICS, INC.
	By:	/s/ Quang X. Pham
	Name:	Quang X. Pham
	Title:	Chairman and Chief Executive Officer

2

FAQ

What did Cadrenal Therapeutics (CVKD) file on August 11, 2025?

Form 8-K (Item 2.02) furnishing a press release with financial information for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Does the 8-K include the quarter's financial numbers for CVKD?

No. The 8-K states a press release containing financial information was furnished as Exhibit 99.1, but the 8-K text does not reproduce the figures.

Is the press release in Exhibit 99.1 considered "filed" or incorporated by reference?

No. The filing expressly states the press release and Item 2.02 disclosure are furnished and shall not be deemed "filed" for Section 18 or incorporated by reference into other SEC filings.

Where is Cadrenal Therapeutics listed and what is its ticker?

The company’s common stock is listed on the Nasdaq Capital Market under the ticker CVKD.

Who signed the Form 8-K for Cadrenal Therapeutics?

The Form 8-K was signed by Quang X. Pham, Chairman and Chief Executive Officer, dated August 11, 2025.